Vital Therapies, a clinical-stage biotech developing treatments for acute liver failure, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The San Diego, CA-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol VTL. Vital Therapies initially filed confidentially on July 22, 2013. Credit Suisse and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
